Morphosys Opts for Second Predevelopment Programme Within Strategic Antibody Alliance
Within its collaboration with Novartis, MorphoSys AG has nominated the second therapeutic antibody programme for joint predevelopment.
Within its collaboration with Novartis, MorphoSys AG has nominated the second therapeutic antibody programme for joint predevelopment. The predevelopment agreement provides MorphoSys with the option to enter a formal co-development for the respective programme with Novartis. Until the programme reaches formal co-development status, Novartis carries all “project-related” costs. MorphoSys’s share of the funded research will add to revenues in its Proprietary Development segment.
The first predevelopment candidate with Novartis was announced in September 2008, giving MorphoSys the opportunity to benefit from working with a very experienced pharmaceutical partner and strengthening its own drug development capabilities.
“The options on predevelopment with Novartis are an important contribution to our proprietary development activities. Including this latest addition to our pipeline, we currently pursue nine proprietary programmes and partnered candidat
Related News
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.